Late Onset Alzheimer Clinical Trial
Official title:
Good Rate of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease After Three Months of Treatment
Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related
disorders, such as Alzheimer's disease (AD), warrant special attention due to their high
prevalence in the elderly. Pharmacologic treatment of AD is based on cholinesterase
inhibitors (ChEI) and memantine, leading to modest clinical benefits both in the short and
long-term.
However, clinical response is heterogeneous and needs further investigation. Objective: To
investigate the rate of response to ChEI in AD after three months of treatment. Methods:
Patients with mild or moderate dementia due to probable AD or to AD associated with
cerebrovascular disease were included in the study.
The subjects were assessed at baseline and again after three months of ChEI treatment. Subjects were submitted to the Mini-Mental State Examination (MMSE), Mattis Dementia Rating Scale, Katz Basic Activities of Daily Living, Pfeffer Functional Activities Questionnaire, Neuropsychiatric Inventory and Cornell Scale for Depression in Dementia. Good response was defined by a gain of ≥2 points on the MMSE after three months of treatment in relation to baseline. ;